jRCT2051220042进行中(未招募)不适用
A Single-Center, Randomised, Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide therapy in the patients with severe right heart failure due to pulmonary hypertension
未提供0 个研究点目标入组 30 人开始时间: 2022年11月2日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 30
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit(—)
- 性别
- All
入选标准
- •Patients who are at least 18 years of age at the time consent is obtained
- •Patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH)
- •Patients who meet all of the following criteria for right heart catheterization
- •Mean pulmonary artery pressure greater than 25 mmHg
- •Pulmonary capillary wedge pressure or left ventricular end-diastolic pressure less than 15 mmHg
- •Pulmonary vascular resistance greater than 3 Wood units
- •WHO-FC III or higher
- •Patients with fluid retention (fluid retention on physical examination or echocardiographic evidence of congestion), low cardiac output (cardiac coefficient less than 2.5 L/min/m2 ), or in need of inotropic drugs
- •Patients with written consent from the patient
排除标准
- •Patients with cardiac disease (Eisenmenger's syndrome) who are completely dependent on a right-left shunt for life support
- •Patients with PAH who are eligible for Calcium channel blockers
- •Patients with pulmonary veno-occlusive disease
- •Patients with pulmonary capillary haemangiomatosis
- •Patients with pulmonary hypertension due to left heart disease
- •Patients with pulmonary hypertension due to pulmonary disease and/or hypoxia
- •Patients with pulmonary hypertension with un clear and/or multifactorial mechanisms
- •Patients with a history of hypersensitivity to the investigational drug
- •Pregnant or lactating women, or patients who cannot consent to contraception during the study
- •Patients who plan to participate in other clinical trials or interventional studies during the period of this study
- •Patients who are judged by the investigator or subinvestigator to be inappropriate to participate in this clinical trial for other reasons.
结局指标
主要结局
-
Efficacy: Change in Pulmonary vascular resistance (PVR) at 30 minutes after inhalation of study drug
次要结局
- Catheter findings(Change from screening time point to each time point (Day 1, Day 2, Day 3))
- SF36(Change to each time point (Day 3, Day 7, Day 8))
研究者
相似试验
招募中
不适用
A randomised controlled trial of nitric oxide administration during cardiopulmonary bypass in neonates undergoing Arterial Switch Operation for repair of transposition of the great arteries.transposition of the great arteriesSurgery - Other surgeryCardiovascular - Other cardiovascular diseasesReproductive Health and Childbirth - Complications of newborncongenital heart diseaseACTRN12618000089235Christopher James800
进行中(未招募)
1 期
Pulsed, inhaled nitric oxide (iNO) for the treatment of patients with mild ormoderate corona virus disease (COVID-19)EUCTR2020-002394-94-BEDr. De Backer Wilfried BV6
已完成
Unknown
Effects of nitric oxide inhalation therapy in the percutaneous ventricular assist device (Impella).JPRN-UMIN000050133Iwate Medical University50
进行中(未招募)
1 期
Therapy with Inhaled Nitric Oxide for Patients Infected with Coronavirus Suffering form Lung FailureARDS caused by COVID-19 infectionEUCTR2020-001329-30-ATMassachussetts General Hospital200
进行中(未招募)
1 期
Inhaled Nitric Oxide Gas Therapy in Respiratory Treated Patients with COVID-19 infectioCOVID-19 infection caused by SARS-CoV-2MedDRA version: 20.0Level: LLTClassification code 10038700Term: Respiratory infectionSystem Organ Class: 100000004862EUCTR2020-001490-68-SEStockholm County Council; Danderyd Hospital40
